NCLH & INO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Notifies Investors of Class Actions and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 31, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH)
Class Period: February 20, 2020 – March 12, 2020
Deadline: May 11, 2020
For more info: www.bgandg.com/nclh.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: 1) Norwegian was employing sales tactics of providing customers with unproven and/or blatantly false statements about COVID-19 to entice customers to purchase cruises, thus endangering the lives of both their customers and crew members; and (2) as a result, defendants' statements regarding Norwegian's business and operations were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
Class Period: February 14, 2020 – March 9, 2020
Deadline: May 11, 2020
For more info: www.bgandg.com/ino

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements about Inovio's development of a purported vaccine for the novel coronavirus, artificially inflating the company's share price and resulting in significant investor losses.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 583041